Back to search
PIK3CA-Related Overgrowth Spectrum (PROS)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33…
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spe…
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chil…
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension period…
The purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term saf…